Skip Navigation

JNCI Monographs 2001 2001(30):135-142;
© 2001 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow An erratum has been published
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Partridge, A. H.
Right arrow Articles by Winer, E. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Partridge, A. H.
Right arrow Articles by Winer, E. P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute Monographs, No. 30, 135-142, 2001
© 2001 Oxford University Press

Side Effects of Chemotherapy and Combined Chemohormonal Therapy in Women With Early-Stage Breast Cancer

Ann H. Partridge, Harold J. Burstein, Eric P. Winer

Affiliations of authors: Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston, MA.

Correspondence to: Eric P. Winer, M.D., Breast Oncology Center, Dana-Farber Cancer Institute, 44 Binney St., Boston, MA 02115 (e-mail: ewiner{at}partners.org).

The decision to receive chemotherapy or chemohormonal therapy involves careful consideration of both the potential benefits and possible risks of therapy. There are substantial short- and long-term side effects from chemotherapy. By convention, short-term side effects include those toxic effects encountered during chemotherapy, while long-term side effects include later complications of treatment arising after the conclusion of adjuvant chemotherapy. These side effects vary, depending on the specific agents used in the adjuvant regimen as well as on the dose used and the duration of treatment. There is also considerable variability in side effect profile across individuals. This review will focus on the short- and long-term toxicity seen with the most commonly used adjuvant chemotherapy and chemohormonal therapy regimens.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
S. L. Hines, B. A. Mincey, J. A. Sloan, S. P. Thomas, E. Chottiner, C. L. Loprinzi, M. D. Carlson, P. J. Atherton, M. Salim, and E. A. Perez
Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Risedronate for the Prevention of Bone Loss in Premenopausal Women Undergoing Chemotherapy for Primary Breast Cancer
J. Clin. Oncol., March 1, 2009; 27(7): 1047 - 1053.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
E. P. Winer, J. R. Harris, B. L. Smith, H. A. D'Alessandro, and E. F. Brachtel
Case 32-2007 -- A 62-Year-Old Woman with a Second Breast Cancer
N. Engl. J. Med., October 18, 2007; 357(16): 1640 - 1648.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.